A Study of Zilovertamab Vedotin (MK-2140) as Monotherapy and in Combination in Participants With Aggressive and Indolent B-cell Malignancies (MK-2140-006)

The main inclusion criteria include, but are not limited to the following:

Inclusion Criteria:

• For aggressive B-cell malignancies mantle cell lymphoma (MCL): Has histologicallyconfirmed biopsy according to the 2016 World Health Organization (WHO)classification of neoplasms of the hematopoietic and lymphoid tissues and hasrelapsed or refractory disease after at least 2 prior systemic therapies including aBruton's tyrosine kinase inhibition/inhibitor(s) (BTKi), and is post chimericantigen receptor T (CAR-T) cell therapy or is ineligible for CAR-T cell therapy.

• For aggressive B-cell malignancies MCL Cohort C: Has histologically confirmed biopsyaccording to the 2016 World Health Organization (WHO) classification of neoplasms ofthe hematopoietic and lymphoid tissues and has relapsed or refractory disease afterat least 1 prior systemic therapy and has no prior exposure to a non-covalent BTKi.

• For aggressive B-cell malignancies Richter transformation lymphoma (RTL): Hashistologically confirmed biopsy according to the 2016 World Health Organization (WHO) classification of neoplasms of the hematopoietic and lymphoid tissues and hasrelapsed or refractory disease.

• For indolent B-cell malignancies follicular lymphoma (FL) and chronic lymphocyticleukemia (CLL): Has histologically confirmed biopsy and has relapsed or refractorydisease after at least 2 prior systemic therapies and no other available therapy.

• Participants who are hepatitis B surface antigen (HBsAg) positive are eligible ifthey have received hepatitis B virus (HBV) antiviral therapy for at least 4 weeksand have undetectable HBV viral load prior to randomization/allocation.

• Have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2assessed within 7 days before cycle 1 day 1.

Exclusion Criteria:

• Has received solid organ transplant at any time.

• Has clinically significant (ie, active) cardiovascular disease: cerebral vascularaccident/stroke (<6 months prior to enrollment), myocardial infarction (<6 monthsprior to enrollment), unstable angina (<6 months prior to enrollment), congestiveheart failure (New York Heart Association Classification Class ≥II), or seriouscardiac arrhythmia requiring medication.

• Has pericardial effusion or clinically significant pleural effusion.

• Has ongoing Grade >1 peripheral neuropathy.

• Has a demyelinating form of Charcot-Marie-Tooth disease.

• Has a history of a second malignancy, unless potentially curative treatment has beencompleted with no evidence of malignancy for 2 years.

• Participants with FL who have transformed to a more aggressive type of lymphoma.

• Has received prior systemic anticancer therapy within 5 half-lives or 4 weeks (ifprior therapy was a monoclonal antibodies) or 2 weeks (if prior therapy was smallmolecules like kinase inhibitors) prior to the first dose of study intervention.

• Has received prior radiotherapy within 28 days of start of study intervention.Participants must have recovered from all radiation-related toxicities.

• Has ongoing corticosteroid therapy exceeding 30 mg daily of prednisone equivalent.

• Has received a live or live-attenuated vaccine within 30 days before the first doseof study intervention.

• Has known active central nervous system (CNS) lymphoma involvement or active CNSinvolvement by lymphoma.

• Has an active infection requiring systemic therapy.

• Has a known history of human immunodeficiency virus (HIV) infection not wellcontrolled on antiretroviral therapy (ART)

• Active HBV or hepatitis C virus (HCV) infection.

• For Cohort C only: has any clinically significant gastrointestinal abnormalitiesthat might alter absorption.